Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $89,100.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $8.91, for a total value of $89,100.00. Following the completion of the transaction, the insider owned 556,887 shares of the company’s stock, valued at approximately $4,961,863.17. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total value of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.00, for a total value of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Price Performance

NASDAQ SOPH opened at $8.28 on Thursday. The company has a 50-day moving average price of $6.70 and a two-hundred day moving average price of $5.53. SOPHiA GENETICS SA has a 52 week low of $3.10 and a 52 week high of $8.98. The stock has a market cap of $694.65 million, a price-to-earnings ratio of -7.20 and a beta of 0.98. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. Analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on SOPH shares. BTIG Research raised their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC grew its position in SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after buying an additional 4,155 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $50,000. Finally, Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS in the 3rd quarter worth about $49,000. 31.59% of the stock is owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.